Experian takes over MyHealthDirect for patient engagement and access
Category: #health  By Pankaj Singh  Date: 2019-08-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Experian takes over MyHealthDirect for patient engagement and access
  • MyHealthDirect’s easy-to-understand technology guides its patients to profound and right care.
  • Acquisition of MyHealthDirect would strengthen Experian’s status as a foremost supplier of solutions which simplify healthcare’s administrative and financial aspects.

Experian, the international information services company, reportedly announced that it has made an agreement to take over MyHealthDirect, which provides a digital care coordination base that enhances scheduling for consumers, providers, and payers.

Acquisition of MyHealthDirect would strengthen Experian’s status as a foremost supplier of solutions which simplify healthcare’s administrative and financial aspects – making the tasks of check-in, registration and scheduling easier, insurance coverage smoother to verify and giving cost estimation more accurate.

MyHealthDirect’s easy-to-understand technology guides its patients to profound and right care, it enables real-time scheduling from every digital access channel: in call centers, in provider offices and on the web. Their systems make it easier for timely care access, meeting customer needs, and creating client efficiencies.

MyHealthDirect customers get an advantage of call center for appointment due to automated management of increasing referral and appointment rates, appointment inventory, decreasing appointment no-shows and improving over-all patient experience.

CEO of MyHealthDirect, Tom Cox stated that MyHealthDirect and Experian would realize mutual benefits around product enhancement and development, market expansion and best data solutions.

Tom also added that the company is looking forward towards the resources of Experian which would speed up the development of products that would create a difference between Experian and its rivals.

Experian Group President supervising Experian Health, Jennifer Schulz stated that aim of Experian Health is to utilize data driven insight to simplify and connect to healthcare for everyone.

Jennifer also added that connecting with MyHealthDirect would then propel how the company delivers on that aim, giving the company potential to evolve patient engagement abilities and front-end patient access by building solutions that improve customer convenience while enhancing care for healthcare providers.

Source Credit:

https://www.experianplc.com/media/news/2019/experian-acquires-myhealthdirect-strengthening-leadership-position-in-patient-access-and-engagement/

 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...